Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Lobe Sciences Stock News

LOBEFOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.0225

-0.00030-1.32%

At close: -

$0.0149

-0.00760-33.78%

After Hours: Oct 29, 9:08 AM EDT

Lobe Sciences (LOBEF) Forecast

News

Earnings Lobe Sciences (LOBEF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Lobe Sciences Stock News | OTC:LOBEF | Benzinga

Get the latest news on Lobe Sciences stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Lobe Sciences performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, January 15, 2024

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Lara Goldstein - Jan 15, 2024, 1:38PM

Tuesday, July 04, 2023

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Lara Goldstein - Jul 4, 2023, 10:21AM

Wednesday, June 28, 2023

This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Lara Goldstein - Jun 28, 2023, 6:27PM

Monday, April 24, 2023

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Lara Goldstein - Apr 24, 2023, 3:57PM

Thursday, April 20, 2023

Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
Lara Goldstein - Apr 20, 2023, 2:24PM

Tuesday, February 28, 2023

Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
Richard Dal Monte - Sponsored

Friday, January 27, 2023

Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
Lara Goldstein - Jan 27, 2023, 1:08PM

Tuesday, November 22, 2022

Lobe Sciences Hopes To Move Novel Psilocin Drug Compounds Quickly Through The FDA Funnel
The Dales Report - Nov 22, 2022, 1:49PM

Friday, October 14, 2022

Proprietary Psychedelic Readies For Trials Targeting Neurologic And Brain Disease
Lara Goldstein - Oct 14, 2022, 10:39AM

Thursday, September 01, 2022

Psychedelics Funding At Its Best: $1.5M Destined To Psilocin Clinical Trials In Australia
Lara Goldstein - Sep 1, 2022, 2:20PM

Wednesday, August 10, 2022

Lobe Sciences Signs Exclusive Deal For Psilocin Clinical Trials In Australia
Lara Goldstein - Aug 10, 2022, 1:31PM

Tuesday, July 19, 2022

Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Lara Goldstein - Jul 19, 2022, 3:51PM

Wednesday, June 15, 2022

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Natan Ponieman - Jun 15, 2022, 12:32PM

Wednesday, June 08, 2022

New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
Lara Goldstein - Jun 8, 2022, 2:35PM

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved